What Do You Want to Know? A Reader's Survey Tells All
Learn what Applied Clinical Trial's readers told us in our annual reader's survey.
What Do You Want to Know? A Reader's Survey Tells AllDid you respond to Applied Clinical Trials' reader survey this year? Well, the results are in and those of you who did respond gave us an inside look into what clinical trials professionals are planning for their businesses in the next year and what they want to learn more about both in print and online.
New strategies that respondent's organizations would be undertaking in the next year to remain competitive included increasing efficiencies with technology (70%) and forming partnerships (58%). The hot topics that people want addressed in the next year are good clinical practice (64%), economic impact on the industry (43%), and eClinical (43%).Delving deeper into article topics, respondents want to see more on regulations, Phase II-III trials, education and training, Phase IV trials/postmarketing, and biotechnology.Check out page 8 to see the lucky respondent who won a flat screen television for participating in Applied Clinical Trials' survey this year.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
